(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-(4-methanesulfonylphenyl)amine

(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-(4-methanesulfonylphenyl)amine is a synthetic small molecule belonging to the pyrazolo[1,5-a]pyrimidine class of heterocyclic compounds. It has been identified as an experimental compound with no current clinical approval or marketed indications. The compound is structurally characterized by a pyrazolopyrimidine core substituted with a chlorine atom and an N-linked 4-methanesulfonylaniline moiety. According to DrugBank and PubChem data, it has been studied in the context of protein kinase inhibition—specifically cyclin-dependent kinase 2 (CDK2)—and may act as an ATP-binding site inhibitor for this target. However, there are no reported clinical trials or approved uses for this molecule as of June 2025. Its primary relevance appears to be in research settings focused on cell cycle regulation and potential anticancer activity through CDK2 inhibition[1][2][3].

Other names

(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-(4-methanesulfonylphenyl)amine5-chloro-N-(4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-amine